Skip to main content
. 2013 May 21;22(2):192–200. doi: 10.1007/s12282-013-0475-1

Table 4.

Summary of tumor response in the ITT population

Best response, n (%)
 CR 0
 PR 12 (24)
 SD, ≥ 24 weeks 18 (35)
 SD, < 24 weeks 14 (27)
 PD 6 (12)
 NE 1 (2)
 ORR 24 % (95 %CI 12.8, 37.5)
 CBR 59 % (95 %CI 44.2, 72.4)

CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, CBR clinical benefit rate (CR; PR; SD ≥ 24 weeks)